| __timestamp | CRISPR Therapeutics AG | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 5078000000 |
| Thursday, January 1, 2015 | 13403000 | 4717000000 |
| Friday, January 1, 2016 | 31056000 | 5096000000 |
| Sunday, January 1, 2017 | 35845000 | 4986000000 |
| Monday, January 1, 2018 | 48294000 | 4214000000 |
| Tuesday, January 1, 2019 | 63488000 | 3806000000 |
| Wednesday, January 1, 2020 | 88208000 | 3671000000 |
| Friday, January 1, 2021 | 102802000 | 3528000000 |
| Saturday, January 1, 2022 | 102464000 | 3445000000 |
| Sunday, January 1, 2023 | 76162000 | 3498000000 |
| Monday, January 1, 2024 | 72977000 | 3702000000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biopharmaceuticals, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG from 2014 to 2023. Over this period, Teva's SG&A expenses have shown a downward trend, decreasing by approximately 31% from 2014 to 2023. In contrast, CRISPR Therapeutics AG has experienced a significant increase, with expenses rising nearly 1,400% over the same period. This divergence highlights the strategic differences in cost management between an established pharmaceutical leader and an innovative biotech firm. As Teva focuses on streamlining operations, CRISPR's growth reflects its investment in expanding its market presence. Understanding these trends provides valuable insights into the financial strategies shaping the future of the biopharmaceutical industry.
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs CRISPR Therapeutics AG Trends and Insights
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Genmab A/S
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Dr. Reddy's Laboratories Limited
Teva Pharmaceutical Industries Limited vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs HUTCHMED (China) Limited
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and CRISPR Therapeutics AG
SG&A Efficiency Analysis: Comparing CRISPR Therapeutics AG and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Perrigo Company plc
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.